Idiopathic urticaria
MONDO:0044211Also known as: idiopathic angioedema-urticaria
67 clinical trials for this condition and its sub-types, 0 tagged with Idiopathic urticaria itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Idiopathic urticaria
-
Chronic idiopathic urticaria 65 trials
-
Acute idiopathic urticaria 1 trial
-
Can a Two-Drug sequence tame chronic hives?
Disease control Not yet recruitingResearchers are testing a treatment plan that uses two drugs, remibrutinib and omalizumab, in adults with chronic spontaneous urticaria whose hives and itching are not controlled by standard antihistamines. The study follows about 382 adults across multiple centers worldwide. The…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new pill quiet stubborn chronic hives?
Disease control Not yet recruitingThis phase II trial tests whether an experimental oral drug called TLL-018 can reduce itching and hives in adults with moderate-to-severe chronic spontaneous urticaria (CSU) that hasn't responded to standard antihistamines. Participants will take either a low or high dose of TLL-…
Phase 2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new pill silence stubborn hives?
Disease control Not yet recruitingThis trial is testing an experimental oral medication called THB335 in adults with chronic spontaneous urticaria (CSU), a condition marked by persistent hives and itching that standard antihistamines don't fully control. Participants will take THB335 or a placebo alongside their …
Phase 2 • Sponsor: Calixis Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can your own blood cure your hives? new trial investigates
Disease control Not yet recruitingThis phase 3 trial tests whether injecting a patient's own blood (autologous whole blood therapy) can help control chronic hives that don't respond to high-dose antihistamines. 40 adults with chronic idiopathic urticaria will receive either the blood injections plus antihistamine…
Phase 3 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill aims to stop chronic hives fast when antihistamines fail
Symptom relief Not yet recruitingThis early-phase trial tests a new drug called TLL-018 in 36 adults with moderate-to-severe chronic spontaneous urticaria (hives) that standard antihistamines can't control. The goal is to see how quickly TLL-018 reduces itching and hives after the first dose. Participants will r…
Phase 1/2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
New pill aims to quiet chronic hives without the itch
Symptom relief Not yet recruitingThis early-stage trial tests an experimental tablet called Alpha-0261 in people with chronic spontaneous urticaria (long-lasting hives) and in healthy volunteers. The study checks the drug's safety, how the body processes it, and whether it reduces hive activity and itching. Part…
Phase 1 • Sponsor: AlphaMol Science Ltd. (Shanghai) • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug HRS-3095 aims to soothe stubborn hives
Symptom relief Not yet recruitingThis Phase 2 trial tests whether the experimental drug HRS-3095 can reduce itching and wheals in adults with chronic spontaneous urticaria (hives) that isn't well controlled by antihistamines. About 190 participants will receive either the drug or a placebo daily for 4 weeks. The…
Phase 2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Could a bacterial extract help tame stubborn hives?
Symptom relief Not yet recruitingThis study looks at whether adding a bacterial lysate (OM-85) to standard antihistamines can better control chronic spontaneous urticaria (CSU), also known as chronic hives. Researchers will observe 132 adults who have not responded well to antihistamines alone. The main goal is …
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New shot could tame stubborn hives for good
Symptom relief Not yet recruitingThis study tests a new medicine called MG-K10 for people with chronic hives (itchy welts) that don't get better with standard allergy pills. About 226 teens and adults will receive either the drug or a placebo injection every few weeks. The goal is to see if MG-K10 reduces itchin…
Phase 3 • Sponsor: Shanghai Mabgeek Biotech.Co.Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Can immune fingerprints unlock new treatments for skin disease?
Knowledge-focused Not yet recruitingThis observational study aims to map the immune and molecular profiles of people with inflammatory skin conditions, including genetic forms like epidermolysis bullosa. By comparing these profiles to those of healthy individuals, researchers hope to identify unique signatures that…
Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC